TransGenic Group

TransGenic Group Dividend Coverage

The Dividend Coverage Ratio of TransGenic Group (2342.T) as of Nov 18, 2026 is -21.81. In the previous year, Dividend Coverage Ratio was 0.08 — a change of -26,774.22% (lower).

Dividend Coverage

-21.81

YoY

-26,774.22%

Last updated:

Dividend Coverage Ratio of TransGenic Group is 2025 -21.81 . Dividend Coverage Ratio of TransGenic Group was 2024 0.08 . It decreases by -26,774.22% lower compared to the previous year.

The TransGenic Group Dividend Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Dividend Coverage
Date
Dividend Coverage
Jan 1, 2021
10.83 JPY
Jan 1, 2022
37.10 JPY
Jan 1, 2023
-8.10 JPY
Jan 1, 2024
0.08 JPY
Jan 1, 2025
-21.81 JPY
The TransGenic Group Dividend Coverage history
YEARDividend CoverageYoY
-21.81-26,774.22%
0.08-101.01%
-8.10-121.84%
37.10+242.66%
10.83—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TransGenic Group Stock analysis

What does TransGenic Group do? TransGenic Group Inc. generates revenue through three business segments. The Contract Research Organization (CRO) segment provides contract clinical tests for pharmaceuticals and foods, including pharmacodynamic and safety pharmacology tests, as well as non-clinical safety tests for pesticides and food. It also offers contract production of genetically modified mice and antibodies, sales of model mice, and development of new biomarkers. The Diagnostic Analysis segment delivers pathological diagnosis services, gene analysis contract services, and drug discovery support for individualized medicine. The TGBS segment provides business succession and revitalization advice and support services, alongside an electronic commerce (EC) business for retail and wholesale of electrical products. The CRO segment serves pharmaceutical and food companies requiring clinical and non-clinical testing services. The Diagnostic Analysis segment targets healthcare providers and researchers needing diagnostic and drug discovery support. The TGBS segment caters to businesses seeking succession planning and revitalization services, while its EC business sells electrical products to retail and wholesale customers. Revenue streams include fees from clinical and safety testing, production of genetically modified animals, sales of model mice, and development of biomarkers under the CRO segment. The Diagnostic Analysis segment earns from pathology services, gene analysis, and drug discovery support. The TGBS segment generates income through advisory services and EC sales of electrical products. TransGenic Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TransGenic Group stock

Dividend Coverage Ratio of TransGenic Group is -21.81 in 2025.

Dividend Coverage Ratio of TransGenic Group changed from 0.08 to -21.81, representing a -26,774.22% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Dividend Coverage Ratio TransGenic Group since 2006 – with annual values, charts, and detailed analysis.

The dividend coverage ratio measures how many times dividends can be covered by net income. Higher coverage suggests more sustainable dividend payments.

Dividend Coverage Ratio's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Dividend Coverage Ratio's TransGenic Group historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dividend — TransGenic Group

All Key Metrics — TransGenic Group